GW Pharmaceuticals PLC Sponsored ADR(NASDAQ : GWPH)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading GWPH News...
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||1.13%||16.59||10.2%||$228.70m|
|SHPG||Shire PLC Sponsored ADR||0.13%||180.89||0.3%||$189.02m|
|PRGO||Perrigo Co. Plc||-0.37%||84.36||4.3%||$142.10m|
|ENDP||Endo International Plc||0.52%||13.26||9.0%||$98.67m|
|PRXL||PAREXEL International Corporation||0.05%||65.83||7.5%||$84.18m|
|UTHR||United Therapeutics Corporation||-9.43%||152.09||13.5%||$77.75m|
|JAZZ||Jazz Pharmaceuticals Plc||-0.85%||134.78||2.3%||$70.77m|
|ICPT||Intercept Pharmaceuticals, Inc.||-0.91%||124.31||21.9%||$66.61m|
|SAGE||SAGE Therapeutics, Inc.||-1.18%||63.31||12.1%||$48.60m|
|GWPH||GW Pharmaceuticals PLC Sponsored ADR||-2.74%||125.88||10.9%||$47.56m|
|SGYP||Synergy Pharmaceuticals, Inc.||-2.32%||5.70||16.1%||$41.64m|
|HZNP||Horizon Pharma plc||0.67%||17.31||11.1%||$40.07m|
|PTLA||Portola Pharmaceuticals, Inc.||-1.93%||32.03||8.8%||$39.81m|
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.